Patients with high-risk asymptomatic early-stage CLL (del(17p) or mutated TP53) do not derive an EFS benefit from early ibrutinib treatment. Watch-and-wait remains standard for early-stage CLL regardless of genetic subgroup; genetic test findings must not prompt early treatment
Among 1,545 women included with a median follow-up of 9.4 years in postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls HR, 0.51, with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed dose was 5mg daily of 10mg every other day in ductal carcinoma in situ (DCIS) and high-risk pts. Less is as good.
955 individuals were screened for eligibility, 747 of whom were randomly assigned to belzutifan–lenvatinib (n=371) or cabozantinib (n=376). 565 (76%)
Combining 177Lu-PSMA-617 with androgen deprivation therapy (ADT) plus androgen receptor pathway inhibitor (ARPI) prolonged radiographic progression-free survival in patients with prostate-specific membrane antigen (PSMA) -positive disease, Radiographic progression-free survival was significantly improved in the 177Lu-PSMA-617 arm vs the control arm, with a 28% reduction in the relative risk of radiographic progression or death (HR 0·72 [95% CI 0·58–0·90]; p=0·0021; dry mouth was the most common side effects. Moving to frontline
The cohort included 229 467 patients; 86 422 (37.7%) received glucagon-like peptide-1 receptor agonist (GLP-1RA), while 143 045 (62.3%) received diet or exercise consultation. With a median follow-up of 2 years (interquartile range 1-2 years), the propensity score matching analysis showed a significantly lower incidence of any Obesity Associated Cancers among GLP-1RA users (hazard ratio 0.59, 95% confidence interval 0.53-0.67). Secondary analyses showed that in all subgroups, except for black race, GLP-1RA use was associated with a lower cumulative incidence of OACs. GLP-1 will be studied more often in cancer patients, some practices, already have GLP-1 clinic as part of their cancer care.
644 patients who are triple-negative breast cancer (TNBC) not candidates for immunotherapy were randomly assigned to receive Dato-DXd (n = 323) or chemotherapy (n = 321). Median progression-free survival (PFS) was 10.8 months with Dato-DXd and 5.6 months with chemotherapy. Median overall survival (OS) was 23.7 months and 18.7 months with Dato-DXd and chemotherapy, respectively HR 0.79; P = 0.029]. Treatment-related adverse events (TRAEs) of grade ≥3 were reported in 105 (33%) and 89 (29%) patients who received Dato-DXd and chemotherapy, respectively, they were more treatment discontinuation in the chemotherapy arm secondary to treatment related adverse events in 14 (4%) and 23 (7%) patients. There were no treatment-related deaths in either arm. New standard of care? Recall this is on patients not eligible for immunotherapy.
Less radiation (40Gy vs 50 Gy) was non inferior in preventing locoregional recurrence and distant mets, also lymphedema rates were not worse. Would love feedback from our rad onc, but it seems less is as good.
Epidermal growth factor receptor (EGFR) and MET are overexpressed in recurrent/metastatic (R/M) head/neck squamous cell cancer (HNSCC).
Subcutaneous amivantamab administered every 3 weeks in participants with non-human papillomavirus R/M HNSCC after PD-(L)1 inhibitor and platinum-based chemotherapy. prior anti EGFR and HPV positive patients were excluded. In 102 participants, blind independent central review assessed objective response rates (ORRs) was 42% (around 20% for second line chemotherapy or cetuximab) the complete response rate was 15%. At a median follow-up of 11.8 months, median progression-free survival (PFS) and overall survival (OS) were 6.8 months and 12.5 months respectively. A non-chemotherapy option for HPV negative patients with promising outcome. Toxicity can still be an issue with those pts
Patients were randomized to Rux placebo vs Rux and selinexor. At week 24, spleen volume reduction ≥35% (SVR35) was achieved in 49.8% of the selinexor plus ruxolitinib group vs 28.0% of the placebo plus ruxolitinib group. Symptom scores improved from baseline in both groups (−9.9 selinexor plus ruxolitinib, −10.9 placebo plus ruxolitinib), with no significant between-group difference will need long term follow up to assess the symptoms relief and the clonal regression.
Progression-free survival (PFS) was higher in the Sun group vs chemotherapy, 10.3 m vs 7.5 m with HR of .65 with higher responses (58.9% vs 31.1%) diarrhea high CK and anemia were the most common side effects. The issue is that amivan was not part of treatment and compared to chemotherapy ami in addition to chemotherapy had 11m PFS also in this trial few had brain mets so no evaluation for CNS protection or treatment. But an oral agent in patients who don’t want to come to the office often.